Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance?

References

• Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. 2009. Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol. 156:1019–1028.
   PubMed Web of Science ®Google Scholar
• Akamine T, Koyanagi S, Kusunose N, Hashimoto H, Taniguchi M, Matsunaga N, Ohdo S. 2015. Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice. J Pharmacol Exp Ther. 354:65–72.
   PubMed Web of Science ®Google Scholar
• Aleksunes LM, Xu J, Lin E, Wen X, Goedken MJ, Slitt AL. 2013. Pregnancy represses induction of efflux transporters in livers of type I diabetic mice. Pharm Res. 30:2209–2220.
   PubMed Web of Science ®Google Scholar
• Anger GJ, Cressman AM, Piquette-Miller M. 2012. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes. PLoS One. 7:e35027
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA. 2014. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 64:1005–1014.
   PubMed Web of Science ®Google Scholar
• Annaba F, Ma K, Kumar P, Dudeja AK, Kineman RD, Shneider BL, Saksena S, Gill RK, Alrefai WA. 2010. Ileal apical Na+-dependent bile acid transporter ASBT is upregulated in rats with diabetes mellitus induced by low doses of streptozotocin. Am J Physiol Gastrointest Liver Physiol. 299:G898–G906.
   PubMed Web of Science ®Google Scholar
• Arinc E, Arslan S, Adali O. 2005. Differential effects of diabetes on CYP2E1 and CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit liver. Arch Toxicol. 79:427–433.
   PubMed Web of Science ®Google Scholar
• Arinc E, Arslan S, Bozcaarmutlu A, Adali O. 2007. Effects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation of carcinogenic activity of N-nitrosodimethylamine in kidney and lung. Food Chem Toxicol. 45:107–118.
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Eisenbarth GS, Michels AW. 2014. Type 1 diabetes. Lancet. 383:69–82.
   PubMed Web of Science ®Google Scholar
• Baek HW, Bae SK, Lee MG, Sohn YT. 2006. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J Pharm Sci. 95:2452–2462.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. 2008. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 83:288–292.
   PubMed Web of Science ®Google Scholar
• Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. 2004. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia. 47:104–112.
   PubMed Web of Science ®Google Scholar
• Borbás T, Benkő B, Dalmadi B, Szabó I, Tihanyi K. 2006. Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Eur J Pharm Sci. 28:51–58.
   PubMed Web of Science ®Google Scholar
• Chatuphonprasert W, Nemoto N, Sakuma T, Jarukamjorn K. 2012. Modulations of cytochrome P450 expression in diabetic mice by berberine. Chem Biol Interact. 196:23–29.
   PubMed Web of Science ®Google Scholar
• Chen SZ, Pan PP, Shen LB, Xu SS, Dai DP, Geng PW, Cai J, Cai JP, Hu GX. 2014. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. Int J Clin Pharmacol Ther. 52:732–738.
   PubMed Web of Science ®Google Scholar
• Chen TG, Tai YT, Chang HC, Hong CT, Chen RM, Chen TL. 2000. Modulation of cytochrome P450-dependent monooxygenases in streptozotocin-induced diabetic hamster: II. Reverse role of insulin in P450 activity and defluorination. Acta Anaesthesiol Sin. 38:65–72.
   PubMedGoogle Scholar
• Chen R, Wang Y, Ning R, Hu J, Liu W, Xiong J, Wu L, Liu J, Hu G, Yang J. 2015. Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway. Xenobiotica. 45:782–793.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL. 2008. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharmaceutics. 5:77–91.
   PubMed Web of Science ®Google Scholar
• Cheng PY, Morgan ET. 2001. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab. 2:165–183.
   PubMed Web of Science ®Google Scholar
• Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. 2011. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 21:837–850.
   PubMed Web of Science ®Google Scholar
• Cobbina E, Akhlaghi F. 2017. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 1:15.
   Google Scholar
• Coughtrie MW. 2016. Function and organization of the human cytosolic sulfotransferase (SULT) family. Chemico-Biological Interactions. 259:2.
   PubMed Web of Science ®Google Scholar
• Dash RP, Ellendula B, Agarwal M, Nivsarkar M. 2015. Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies. Eur J Pharmacol. 767:67–76.
   PubMed Web of Science ®Google Scholar
• Davidson MD, Ballinger KR, Khetani SR. 2016. Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. Sci Rep. 6:28178
   PubMed Web of Science ®Google Scholar
• Do MT, Kim HG, Tran TT, Khanal T, Choi JH, Chung YC, Jeong TC, Jeong HG. 2014. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol. 280:138–148.
   PubMed Web of Science ®Google Scholar
• Dominguez E, Galmozzi A, Chang JW, Hsu K-L, Pawlak J, Li W, Godio C, Thomas J, Partida D, Niessen S, et al. 2014. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nat Chem Biol. 10:113–121.
   PubMed Web of Science ®Google Scholar
• Donath MY. 2014. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 13:465–476.
   PubMed Web of Science ®Google Scholar
• Dong B, Qatanani M, Moore DD. 2009. Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology. 50:622–629.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court MH, Hazarika S, Akhlaghi F. 2011b. Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 39:448–455.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court MH, Yan B, Akhlaghi F. 2011a. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol. 163:937–947.
   PubMed Web of Science ®Google Scholar
• Friedrichsen M, Poulsen P, Wojtaszewski J, Hansen PR, Vaag A, Rasmussen HB. 2013. Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function. PLoS One. 8:e56861
   PubMed Web of Science ®Google Scholar
• Gandhi A, Moorthy B, Ghose R. 2012. Drug disposition in pathophysiological conditions. Curr Drug Metab. 13:1327–1344.
   PubMed Web of Science ®Google Scholar
• Gangopadhyay A, Thamotharan M, Adibi SA. 2002. Regulation of oligopeptide transporter (Pept-1) in experimental diabetes. Am J Physiol Gastrointest Liver Physiol. 283:G133–G138.
   PubMed Web of Science ®Google Scholar
• Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. 2012. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 22:820–827.
   PubMed Web of Science ®Google Scholar
• Grover B, Buckley D, Buckley AR, Cacini W. 2004. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther. 308:949–956.
   PubMed Web of Science ®Google Scholar
• Hannon-Fletcher MP, O'Kane MJ, Moles KW, Barnett YA, Barnett CR. 2001. Lymphocyte cytochrome P450-CYP2E1 expression in human IDDM subjects. Food Chem Toxicol. 39:125–132.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, Inotsume N, Takeuchi Y, Fukushima S. 2010a. The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver. Biol Pharm Bull. 33:153–156.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, Inotsume N, Takeuchi Y, Fukushima S. 2010b. Effects of insulin on CYP3A activity and nicardipine disposition in streptozotocin-induced diabetic rats. J Pharm Pharmacol. 62:883–889.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, Nomura H, Ishii Y, Onishi M, Inotsume N, Takeuchi Y, Fukushima S. 2010c. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. J Pharm Pharmacol. 62:310–314.
   PubMed Web of Science ®Google Scholar
• Haufroid V, Ligocka D, Buysschaert M, Horsmans Y, Lison D. 2003. Cytochrome P4502E1 (CYP2E1) expression in peripheral blood lymphocytes: evaluation in hepatitis C and diabetes. Eur J Clin Pharmacol. 59:29–33.
   PubMed Web of Science ®Google Scholar
• He YL. 2012. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 51:147–162.
   PubMed Web of Science ®Google Scholar
• He L, Yang Y, Guo C, Yao D, Liu HH, Sheng JJ, Zhou WP, Ren J, Liu XD, Pan GY. 2014. Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus. Eur J Pharmacol. 724:185–192.
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Macdonald GA. 2007. Impact of diabetes on the severity of liver disease. Am J Med. 120:829–834.
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. 2007. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 35:1333–1340.
   PubMed Web of Science ®Google Scholar
• Hirota T, Eguchi S, Ieiri I. 2013. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet. 28:28–37.
   PubMed Web of Science ®Google Scholar
• Holstein A, Beil W, Kovacs P. 2012. CYP2C metabolism of oral antidiabetic drugs-impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 8:1549–1563.
   PubMed Web of Science ®Google Scholar
• Hu N, Hu M, Duan R, Liu C, Guo H, Zhang M, Yu Y, Wang X, Liu L, Liu X. 2014. Increased levels of fatty acids contributed to induction of hepatic CYP3A4 activity induced by diabetes - in vitro evidence from HepG2 cell and Fa2N-4 cell lines. J Pharmacol Sci. 124:433–444.
   PubMed Web of Science ®Google Scholar
• Iber H, Li-Masters T, Chen Q, Yu S, Morgan ET. 2001. Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation. J Pharmacol Exp Ther. 297:174–180.
   PubMed Web of Science ®Google Scholar
• International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9:215–236.
   Google Scholar
• Ismail-Beigi F. 2012. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 366:1319–1327.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. 2014. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 383:1068–1083.
   PubMed Web of Science ®Google Scholar
• Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, Wakusawa S. 2008. Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim Biophys Acta. 1782:355–360.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW. 2013. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 76:432–444.
   PubMed Web of Science ®Google Scholar
• Kataoka S, Yasui H, Hiromura M, Sakurai H. 2005. Effect of insulin-mimetic vanadyl sulfate on cytochrome P450 2E1-dependent p-nitrophenol hydroxylation in the liver microsomes of streptozotocin-induced type 1 diabetic rats. Life Sci. 77:2814–2829.
   PubMed Web of Science ®Google Scholar
• Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. 2005. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci. 26:114–123.
   PubMed Web of Science ®Google Scholar
• Kim YC, Oh EY, Kim SH, Lee MG. 2006. Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. Biopharm Drug Dispos. 27:85–92.
   PubMed Web of Science ®Google Scholar
• Kinaan M, Ding H, Triggle CR. 2015. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Med Princ Pract. 24:401–415.
   PubMed Web of Science ®Google Scholar
• Knights KM, Rowland A, Miners JO. 2013. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol. 76:587–602.
   PubMed Web of Science ®Google Scholar
• Kobori T, Harada S, Nakamoto K, Tokuyama S. 2013. Functional alterations of intestinal P-glycoprotein under diabetic conditions. Biol Pharm Bull. 36:1381–1390.
   PubMed Web of Science ®Google Scholar
• Koide CL, Collier AC, Berry MJ, Panee J. 2011. The effect of bamboo extract on hepatic biotransforming enzymes–findings from an obese-diabetic mouse model. J Ethnopharmacol. 133:37–45.
   PubMed Web of Science ®Google Scholar
• Konig J, Muller F, Fromm MF. 2013. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 65:944–966.
   PubMed Web of Science ®Google Scholar
• Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB. 2013. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 33:210–222.
   PubMed Web of Science ®Google Scholar
• Lam JL, Jiang Y, Zhang T, Zhang EY, Smith BJ. 2010. Expression and functional analysis of hepatic cytochromes P450, nuclear receptors, and membrane transporters in 10- and 25-week-old db/db mice. Drug Metab Dispos. 38:2252–2258.
   PubMed Web of Science ®Google Scholar
• Lee DY, Chung HJ, Choi YH, Lee U, Kim SH, Lee I, Lee MG. 2009. Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. Eur J Pharm Sci. 38:465–471.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee A, Oh JH, Lee YJ. 2012. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats. Biopharm Drug Dispos. 33:474–486.
   PubMed Web of Science ®Google Scholar
• Lee DY, Lee MG, Shin HS, Lee I. 2007. Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharm Sci. 10:420–433.
   PubMed Web of Science ®Google Scholar
• Li Y, Zalzala M, Jadhav K, Xu Y, Kasumov T, Yin L, Zhang Y. 2016. Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. Hepatology. 63:1860–1874.
   PubMed Web of Science ®Google Scholar
• Liang Y, Li S, Chen L. 2015. The physiological role of drug transporters. Protein Cell. 6:334–350.
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 42:59–98.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu XD. 2014. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 5:273.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu X, Jia L, Liu Y, Yang H, Wang G, Xie L. 2008. Insulin therapy restores impaired function and expression of P-glycoprotein in blood-brain barrier of experimental diabetes. Biochem Pharmacol. 75:1649–1658.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu L, Li J, Mei D, Duan R, Hu N, Guo H, Zhong Z, Liu X. 2012. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 40:1104–1112.
   PubMed Web of Science ®Google Scholar
• Liu YC, Liu HY, Yang HW, Wen T, Shang Y, Liu XD, Xie L, Wang GJ. 2007. Impaired expression and function of breast cancer resistance protein (Bcrp) in brain cortex of streptozocin-induced diabetic rats. Biochem Pharmacol. 74:1766–1772.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu B, Pan G, He L, Li Z, Fan M, Jian L, Chen M, Wang K, Huang C. 2012. Metabolism and pharmacokinetics of mangiferin in conventional rats, pseudo-germ-free rats, and streptozotocin-induced diabetic rats. Drug Metab Dispos. 40:2109–2118.
   PubMed Web of Science ®Google Scholar
• Liu H, Xu X, Yang Z, Deng Y, Liu X, Xie L. 2006. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Res. 1123:245–252.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang D, Xu X, Liu X, Wang G, Xie L, Pang X, Liu L. 2007. Attenuated function and expression of P-glycoprotein at blood-brain barrier and increased brain distribution of phenobarbital in streptozotocin-induced diabetic mice. Eur J Pharmacol. 561:226–232.
   PubMed Web of Science ®Google Scholar
• Lungkaphin A, Arjinajarn P, Pongchaidecha A, Srimaroeng C, Chatsudthipong L, Chatsudthipong V. 2014. Impaired insulin signaling affects renal organic anion transporter 3 (Oat3) function in streptozotocin-induced diabetic rats. PLoS One. 9:e96236
   PubMed Web of Science ®Google Scholar
• Lungkaphin A, Arjinajarn P, Srimaroeng C, Chatsudthipong V. 2012. Function and expression of renal organic anion transporters in experimental diabetes in mice. Scienceasia. 38:18–23. English.
   Web of Science ®Google Scholar
• Ma Q, Lu AY. 2007. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos. 35:1009–1016.
   PubMed Web of Science ®Google Scholar
• Maeng HJ, Kim MH, Jin HE, Shin SM, Tsuruo T, Kim SG, Kim DD, Shim CK, Chung SJ. 2007. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos. 35:1996–2005.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2:875–894.
   PubMed Web of Science ®Google Scholar
• Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. 2000. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy. 20:182–190.
   PubMed Web of Science ®Google Scholar
• Mei D, Li J, Liu H, Liu L, Wang X, Guo H, Liu C, Duan R, Liu X. 2012. Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. Xenobiotica. 42:709–718.
   PubMed Web of Science ®Google Scholar
• Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. 2003. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J Pharmacol Exp Ther. 306:941–947.
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W, Fernandez-Real JM. 2011. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 60:168–176.
   PubMed Web of Science ®Google Scholar
• Nathan DM. 2015. Diabetes: Advances in Diagnosis and Treatment. JAMA. 314:1052–1062.
   PubMed Web of Science ®Google Scholar
• Nawa A, Fujita Hamabe W, Tokuyama S. 2010. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci. 86:402–409.
   PubMed Web of Science ®Google Scholar
• Nawa A, Fujita-Hamabe W, Tokuyama S. 2011. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci. 89:834–838.
   PubMed Web of Science ®Google Scholar
• Nawa A, Fujita-Hamabe W, Tokuyama S. 2011. Regulatory action of nitric oxide synthase on ileal P-glycoprotein expression under streptozotocin-induced diabetic condition. Biol Pharm Bull. 34:436–438.
   PubMed Web of Science ®Google Scholar
• Nawa A, Fujita-Hamabe W, Tokuyama S. 2012. Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse model. Drug Metab Pharmacokinet. 27:548–552.
   PubMed Web of Science ®Google Scholar
• Nigam SK. 2015. What do drug transporters really do?. Nat Rev Drug Discov. 14:29–44.
   PubMed Web of Science ®Google Scholar
• Nolan CJ, Damm P, Prentki M. 2011. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 378:169–181.
   PubMed Web of Science ®Google Scholar
• Nowicki MT, Aleksunes LM, Sawant SP, Dnyanmote AV, Mehendale HM, Manautou JE. 2008. Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett. 2:11–17.
   PubMedGoogle Scholar
• Oh SJ, Choi JM, Yun KU, Oh JM, Kwak HC, Oh JG, Lee KS, Kim BH, Heo TH, Kim SK. 2012. Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats. Chem Biol Interact. 195:173–179.
   PubMed Web of Science ®Google Scholar
• Pandey V, Chaube B, Bhat MK. 2011. Hyperglycemia regulates MDR-1, drug accumulation and ROS levels causing increased toxicity of carboplatin and 5-fluorouracil in MCF-7 cells. J Cell Biochem. 112:2942–2952.
   PubMed Web of Science ®Google Scholar
• Park EC, Kim SI, Hong Y, Hwang JW, Cho GS, Cha HN, Han JK, Yun CH, Park SY, Jang IS, et al. 2014. Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice. Gastroenterology. 147:860–869.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim CH, Lee JY, Jeon JS, Kim MJ, Chae SH, Kim HC, Oh SJ, Kim SK. 2016. Hepatic expression of cytochrome P450 in Zucker diabetic fatty rats. Food Chem Toxicol. 96:244–253.
   PubMed Web of Science ®Google Scholar
• Pass GJ, Becker W, Kluge R, Linnartz K, Plum L, Giesen K, Joost HG. 2002. Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross population. J Pharmacol Exp Ther. 302:442–450.
   PubMed Web of Science ®Google Scholar
• Patoine D, Petit M, Pilote S, Picard F, Drolet B, Simard C. 2014. Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes. Pharmacol Res Perspect. 2:e00082.
   PubMedGoogle Scholar
• Pattanawongsa A, Chau N, Rowland A, Miners JO. 2015. Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions. Drug Metab Dispos. 43:1468–1476.
   PubMed Web of Science ®Google Scholar
• Phatchawan A, Chutima S, Varanuj C, Anusorn L. 2014. Decreased renal organic anion transporter 3 expression in type 1 diabetic rats. Am J Med Sci. 347:221–227.
   PubMed Web of Science ®Google Scholar
• Pociot F, Lernmark A. 2016. Genetic risk factors for type 1 diabetes. Lancet. 387:2331–2339.
   PubMed Web of Science ®Google Scholar
• Pryor R, Cabreiro F. 2015. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 471:307–322.
   PubMed Web of Science ®Google Scholar
• Pucci L, Chirulli V, Marini S, Lucchesi D, Penno G, Gervasi PG, Del Prato S, Longo V. 2005. Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacol Res. 51:561–565.
   PubMed Web of Science ®Google Scholar
• Quezada C, Alarcon S, Carcamo JG, Yanez A, Casanello P, Sobrevia L, San MR. 2011. Increased expression of the multidrug resistance-associated protein 1 (MRP1) in kidney glomeruli of streptozotocin-induced diabetic rats. Biol Chem. 392:529–537.
   PubMed Web of Science ®Google Scholar
• Raza H, Ahmed I, John A, Sharma AK. 2000. Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract. J Biochem Mol Toxicol. 14:131–139.
   PubMed Web of Science ®Google Scholar
• Reichel V, Burghard S, John I, Huber O. 2011. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 1370:238–245.
   PubMed Web of Science ®Google Scholar
• Rubio-Aliaga I, Daniel H. 2008. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica. 38:1022–1042.
   PubMed Web of Science ®Google Scholar
• Runge-Morris M, Kocarek TA, Falany CN. 2013. Regulation of the cytosolic sulfotransferases by nuclear receptors. Drug Metab Rev. 45:15–33.
   PubMed Web of Science ®Google Scholar
• Sakuma T, Honma R, Maguchi S, Tamaki H, Nemoto N. 2001. Different expression of hepatic and renal cytochrome P450s between the streptozotocin-induced diabetic mouse and rat. Xenobiotica. 31:223–237.
   PubMed Web of Science ®Google Scholar
• Schafer A, Galuppo P, Fraccarollo D, Vogt C, Widder JD, Pfrang J, Tas P, Barbosa-Sicard E, Ruetten H, Ertl G, et al. 2010. Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes. 59:2001–2009.
   PubMed Web of Science ®Google Scholar
• Sheweita SA, Newairy AA, Mansour HA, Yousef MI. 2002. Effect of some hypoglycemic herbs on the activity of phase I and II drug-metabolizing enzymes in alloxan-induced diabetic rats. Toxicology. 174:131–139.
   PubMed Web of Science ®Google Scholar
• Sindhu RK, Koo JR, Sindhu KK, Ehdaie A, Farmand F, Roberts CK. 2006. Differential regulation of hepatic cytochrome P450 monooxygenases in streptozotocin-induced diabetic rats. Free Radic Res. 40:921–928.
   PubMed Web of Science ®Google Scholar
• Suh YH, Kim Y, Bang JH, Choi KS, Lee JW, Kim WH, Oh TJ, An S, Jung MH. 2005. Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats. J Mol Endocrinol. 34:299–315.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. 2006. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 72:148–154.
   PubMed Web of Science ®Google Scholar
• Swanson HI. 2015. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?. Drug Metab Dispos. 43:1499–1504.
   PubMed Web of Science ®Google Scholar
• Takatori A, Akahori M, Kawamura S, Itagaki S, Yoshikawa Y. 2002. The effects of diabetes with hyperlipidemia on P450 expression in APA hamster livers. J Biochem Mol Toxicol. 16:174–181.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Tikellis C, Burns WC, Thallas V, Forbes JM, Cao Z, Osicka TM, Russo LM, Jerums G, Ghabrial H, et al. 2003. Reduced tubular cation transport in diabetes: prevented by ACE inhibition. Kidney Int. 63:2152–2161.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Tikellis C, Kantharidis P, Burns WC, Cooper ME, Forbes JM. 2004. The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J Pharmacol Exp Ther. 311:456–466.
   PubMed Web of Science ®Google Scholar
• Tramonti G, Xie P, Wallner EI, Danesh FR, Kanwar YS. 2006. Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am J Physiol Renal Physiol. 291:F972–F980.
   PubMed Web of Science ®Google Scholar
• Ueyama J, Wang D, Kondo T, Saito I, Takagi K, Takagi K, Kamijima M, Nakajima T, Miyamoto K, Wakusawa S, et al. 2007. Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett. 170:229–237.
   PubMed Web of Science ®Google Scholar
• Urry E, Jetter A, Landolt HP. 2016. Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake. Nutr Metab (Lond)). 13:66
   PubMed Web of Science ®Google Scholar
• van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, Bloks V, Muller M, Sauer PJ, Kuipers F. 2002. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology. 122:1842–1852.
   PubMed Web of Science ®Google Scholar
• Vetere A, Choudhary A, Burns SM, Wagner BK. 2014. Targeting the pancreatic β-cell to treat diabetes . Nat Rev Drug Discov. 13:278–289.
   PubMed Web of Science ®Google Scholar
• Wagner DJ, Hu T, Wang J. 2016. Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res. 111:237–246.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. 2003. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol. 55:77–85.
   PubMed Web of Science ®Google Scholar
• Wang JP, Liu IM, Tzeng TF, Cheng JT. 2002. Decrease in catechol-O-methyltransferase activity in the liver of streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 29:419–422.
   PubMed Web of Science ®Google Scholar
• Wang T, Shankar K, Ronis MJ, Mehendale HM. 2000. Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1. J Pharmacol Exp Ther. 294:473–479.
   PubMed Web of Science ®Google Scholar
• Wu KC, Pan HJ, Yin HS, Chen MR, Lu SC, Lin CJ. 2009. Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes. Life Sci. 85:775–781.
   PubMed Web of Science ®Google Scholar
• Xie H, Sun S, Cheng X, Yan T, Zheng X, Li F, Qi Q, Wang G, Hao H. 2013. Dysregulations of intestinal and colonic UDP-glucuronosyltransferases in rats with type 2 diabetes. Drug Metab Pharmacokinet. 28:427–434.
   PubMed Web of Science ®Google Scholar
• Xiong J, Shang W, Wu L, Chen R, Liu W, Ning R, Hu G, Yang J. 2014. Glucose dominates the regulation of carboxylesterases induced by lipopolysaccharide or interleukin-6 in primary mouse hepatocytes. Life Sci. 112:41–48.
   PubMed Web of Science ®Google Scholar
• Xu J, Li Y, Chen WD, Xu Y, Yin L, Ge X, Jadhav K, Adorini L, Zhang Y. 2014. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology. 59:1761–1771.
   PubMed Web of Science ®Google Scholar
• Xu D, Li F, Zhang M, Zhang J, Liu C, Hu MY, Zhong ZY, Jia LL, Wang DW, Wu J, et al. 2014. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin. 35:1215–1225.
   PubMed Web of Science ®Google Scholar
• Xu J, Yin L, Xu Y, Li Y, Zalzala M, Cheng G, Zhang Y. 2014. Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels. PLoS One. 9:e109663
   PubMed Web of Science ®Google Scholar
• Xu C, Zhu L, Chan T, Lu X, Shen W, Gillies MC, Zhou F. 2015. The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice. PLoS One. 10:e0120760
   PubMed Web of Science ®Google Scholar
• Yacovino LL, Aleksunes LM. 2012. Renal efflux transporter expression in pregnant mice with Type I diabetes. Toxicol Lett. 211:304–311.
   PubMed Web of Science ®Google Scholar
• Yalcin EB, More V, Neira KL, Lu ZJ, Cherrington NJ, Slitt AL, King RS. 2013. Downregulation of sulfotransferase expression and activity in diseased human livers. Drug Metab Dispos. 41:1642–1650.
   PubMed Web of Science ®Google Scholar
• Yao HT, Lin P, Chang YW, Chen CT, Chiang MT, Chang L, Kuo YC, Tsai HT, Yeh TK. 2009. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes. Food Chem Toxicol. 47:1703–1709.
   PubMed Web of Science ®Google Scholar
• Yeh SY, Pan HJ, Lin CC, Kao YH, Chen YH, Lin CJ. 2012. Hyperglycemia induced down-regulation of renal P-glycoprotein expression. Eur J Pharmacol. 690:42–50.
   PubMed Web of Science ®Google Scholar
• Yoshinari K, Takagi S, Sugatani J, Miwa M. 2006. Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice. Biol Pharm Bull. 29:1634–1638.
   PubMed Web of Science ®Google Scholar
• Yu XH, Qian K, Jiang N, Zheng XL, Cayabyab FS, Tang CK. 2014. ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. Clin Chim Acta. 428:82–88.
   PubMed Web of Science ®Google Scholar
• Yu S, Yu Y, Liu L, Wang X, Lu S, Liang Y, Liu X, Xie L, Wang G. 2010. Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med. 76:876–881.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Lu L, Jin S, Jing XY, Yao D, Hu N, Liu L, Duan R, Liu XD, Wang GJ, et al. 2011. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats. Acta Pharmacol Sin. 32:956–966.
   PubMed Web of Science ®Google Scholar
• Zhou X, Rougee LR, Bedwell DW, Cramer JW, Mohutsky MA, Calvert NA, Moulton RD, Cassidy KC, Yumibe NP, Adams LA, et al. 2016. Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats. Drug Metab Dispos. 44:1184–1192.
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Magliano DJ, Bennett PH. 2016. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 12:616–622.
   PubMed Web of Science ®Google Scholar